QR код

Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys

Mucopolysaccharidosis Type IIIB (MPS IIIB) is an ultrarare, fatal pediatric disease with no approved therapy. It is caused by mutations in the gene encoding for lysosomal enzyme alpha-N-acetylglucosaminidase (NAGLU). Tralesinidase alfa (TA) is a fusion protein comprised of recombinant NAGLU and a mo...

Повний опис

Збережено в:
Автори: Jason Pinkstaff, Emma McCullagh, Anita Grover, Andrew C. Melton, Anu Cherukuri, Jill CM Wait, Annalisa Nguyen, Mark T. Butt, Jami L. Trombley, Randall P. Reed, Eric.L. Adams, Robert B. Boyd, Sundeep Chandra, Joshua Henshaw, Charles A. O’Neill, Eric Zanelli, Joseph Kovalchin
Формат: Artigo
Мова:Inglês
Опубліковано: Elsevier 2023-01-01
Серія:Toxicology Reports
Предмети:
MPS IIIB
Sanfilippo syndrome
NAGLU
Intracerebroventricular
Enzyme replacement therapy
Онлайн доступ:http://www.sciencedirect.com/science/article/pii/S2214750023000288
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси